For comments, suggestions
Created with Raphaël 2.1.0 15.02.2018 Filing date 14.08.2019 Validation fee payment 29.02.2020 (A1) Patent application published 14.12.2022 AGEPI application filing date 28.02.2023 (T2) Translation of the validated European patent 25.05.2025 15.02.2026 Valid until 16.02.2027 Renewal fee to be paid until 15.02.2038 Patent will expire on

Patent in force


(210)Number of the EPO application18708025
(220)Filing date of the EPO application2018.02.15
(80)EPO patent specification publication (B)EPB nr. 40/2022, 2022.10.05
(110)EPO patent number3583120
(11)Number of the documentMD 3583120 T2
(21)Number of the applicatione 2020 0008
(71)Name(s) of applicant(s), code of the countryDenali Therapeutics Inc., US;
(72)Name(s) of inventor(s), code of the countryCHEN Xiaocheng, US;
DENNIS Mark S., US;
KARIOLIS Mihalis, US;
SILVERMAN Adam P., US;
SRIVASTAVA Ankita, US;
WATTS Ryan J., US;
WELLS Robert C., US;
ZUCHERO Joy Yu, US;
(73)Name(s) of owner(s), code of the countryDenali Therapeutics Inc., US;
(54)Title of the inventionEngineered transferrin receptor binding polypeptides
(13)Kind-of-document code T2
(51)International Patent Classification C07K 14/79 (2006.01.01); C07K 14/705 (2006.01.01); A61K 38/00 (2006.01.01); A61K 39/00 (2006.01.01)
(19)CountryUS
(41)Date of publication of the application2020.02.29
(49)Date of publication of the translation of the validated European patent specification2023.02.28
(30)Priority201762460692 P, 2017.02.17, US; 201762543658 P, 2017.08.10, US; 201762583314 P, 2017.11.08, US
(74)Patent attorney(Procedură) SOCOLOVA Sofia, Str. Drumul Viilor nr. 42, bloc 3, ap. 60, MD-2021, Chişinău, Republica Moldova
(86)International applicationPCT/US2018/018371, 2018.02.15
(87)International publicationWO 2018/152326, 2018.08.23
Up
/Inventions/details/3583120